- Home
- MAX vs DAWN Comparison
MAX vs DAWN Comparison
Compare MAX & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- DAWN
- Stock Information
- Founded
- MAX 2014
- DAWN 2018
- Country
- MAX United States
- DAWN United States
- Employees
- MAX N/A
- DAWN N/A
- Industry
- MAX Industrial Machinery/Components
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- DAWN Health Care
- Exchange
- MAX Nasdaq
- DAWN Nasdaq
- Market Cap
- MAX 551.1M
- DAWN 624.8M
- IPO Year
- MAX 2020
- DAWN 2021
- Fundamental
- Price
- MAX $12.69
- DAWN $9.00
- Analyst Decision
- MAX Buy
- DAWN Strong Buy
- Analyst Count
- MAX 6
- DAWN 8
- Target Price
- MAX $17.00
- DAWN $27.63
- AVG Volume (30 Days)
- MAX 570.7K
- DAWN 1.9M
- Earning Date
- MAX 10-29-2025
- DAWN 11-04-2025
- Dividend Yield
- MAX N/A
- DAWN N/A
- EPS Growth
- MAX N/A
- DAWN N/A
- EPS
- MAX N/A
- DAWN N/A
- Revenue
- MAX $1,123,093,000.00
- DAWN $133,672,000.00
- Revenue This Year
- MAX $27.56
- DAWN $12.88
- Revenue Next Year
- MAX $10.79
- DAWN $48.27
- P/E Ratio
- MAX N/A
- DAWN N/A
- Revenue Growth
- MAX 64.86
- DAWN 31.11
- 52 Week Low
- MAX $7.33
- DAWN $5.64
- 52 Week High
- MAX $13.85
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- MAX 61.96
- DAWN 69.40
- Support Level
- MAX $12.14
- DAWN $7.11
- Resistance Level
- MAX $13.85
- DAWN $10.00
- Average True Range (ATR)
- MAX 0.56
- DAWN 0.50
- MACD
- MAX 0.23
- DAWN 0.16
- Stochastic Oscillator
- MAX 67.49
- DAWN 67.90
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.